Somna Therapeutics is a healthcare startup established in March 2012 in collaboration with the Medical College of Wisconsin. The company's focus is on providing non-invasive medical devices to enhance the quality of life for individuals suffering from laryngopharyngeal reflux (LPR) and extraesophageal acid reflux disease (EERD). Their flagship product, the Reza Band™, UES Assist Device, aims to offer a non-invasive solution for these conditions.
With the recent $1.70M Series D investment on 27 December 2018, backed by 30Ventures and Alumni Ventures, Somna Therapeutics aims to utilize the investment to optimize product design and conduct clinical trials for FDA clearance. The company's roadmap includes obtaining FDA approval and launching the product, after which the focus will be on marketing the device to hospitals, physician clinics, and home health care providers.
Key Information: Name: Somna Therapeutics Slogan: Advancing non-invasive solutions for improved quality of life in LPR/EERD sufferers Founded: 2012 Industries: Health Care Last Investment: $1.70M Series D investment at 27 December 2018 Last Investment Investors: 30Ventures, Alumni VenturesFunding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Series D | $1.70M | 2 | Alumni Ventures | 27 Dec 2018 |
Venture Round | $1.23M | - | 01 Jan 2017 | |
Venture Round | $1.01M | - | 01 Jan 2016 | |
Seed Round | $995.29K | - | 15 Sep 2015 | |
Seed Round | $2.00M | - | 01 Jan 2015 |
No recent news or press coverage available for Somna Therapeutics.